Capricor Therapeutics Updates Shareholders on Class Action Rights

Author: Ryan Hughes Updated: 08-04-2025 04:49 PM

Essential Information for Capricor Therapeutics Investors

Attention shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR): there are critical developments regarding potential class action rights that warrant your attention. If you acquired shares of CAPR during the defined class period, it is vital to explore your options for recovery.

Class Action Overview and Shareholder Encouragement

The Gross Law Firm has reached out to shareholders encouraging them to contact them to discuss possible lead plaintiff appointments. Remember, becoming a lead plaintiff is not a requisite to be part of the recovery.

Notification of the Class Period

CLASS PERIOD: October 9, 2024, to July 10, 2025. Shareholders who purchased during this timeframe are urged to reach out and ensure their rights are protected.

Key Allegations Against Capricor Therapeutics

The ongoing lawsuit includes serious allegations claiming that Capricor Therapeutics provided misleading information regarding its lead cell therapy candidate, deramiocel, intended for treating cardiomyopathy linked with Duchenne muscular dystrophy (DMD). While conveying optimistic projections about obtaining a Biologics License Application (BLA) from the U.S. FDA, the company allegedly obscured critical safety and efficacy data from its Phase 2 HOPE-2 trial.

Impact of FDA's Complete Response Letter

Capricor received a Complete Response Letter from the FDA indicating that the BLA application did not meet the required evidence for effectiveness and highlighted the need for additional data. Following this announcement on July 11, 2025, Capricor's stock plummeted from $11.40 to $7.64 per share. This drastic decline underlines the significance of the information surrounding the class action.

The Gross Law Firm's Commitment

WHY CHOOSE THE GROSS LAW FIRM? The Gross Law Firm is recognized nationally in the realm of class action litigation. Its commitment is to advocate fervently for investors who have borne losses due to deceptive statements and practices. The firm fights vigorously to ensure that companies uphold ethical business standards and exercise responsibility.

Next Steps for Investors

As a shareholder in CAPR, registering your details is a crucial step in safeguarding your rights. Once you sign up, you’ll benefit from monitoring throughout the case's progress without incurring any fees. Be mindful of the pressing registration deadline; September 15, 2025, is the last day to express your interest in being a lead plaintiff.

Contact Information for Inquiries

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Frequently Asked Questions

What is the class action regarding?

The class action involves allegations of misleading statements made by Capricor Therapeutics about their lead therapy candidate, deramiocel.

What should I do as a shareholder of CAPR?

If you purchased shares during the specified class period, it’s important to register your information to protect your rights.

Is there a cost to participate in the class action?

No, participation in the class action is free and carries no obligations.

What is the deadline to register?

The deadline to register for the class action is September 15, 2025.

Why should I contact The Gross Law Firm?

The Gross Law Firm specializes in representing investors in class action cases, offering expertise and a strong commitment to investor rights.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.